| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/01/2003 | US20030082219 Applying active materials to an absorber; cosmetics |
| 05/01/2003 | US20030082215 Fenofibrate galenic formulations and method for obtaining same |
| 05/01/2003 | US20030082214 Oil in water emulsion containing antidepressant, anesthetics |
| 05/01/2003 | US20030082211 Polysaccharide antigen in carrier |
| 05/01/2003 | US20030082198 Administering complex of heat shock protein and antigen |
| 05/01/2003 | US20030082197 Administering complex of heat shock protein and antigen |
| 05/01/2003 | US20030082192 Multidrug multiligand conjugates for targeted drug delivery |
| 05/01/2003 | US20030082191 Treatment for central nervous system disorders |
| 05/01/2003 | US20030082187 Combined cancer treatment methods using antibodies to aminophospholipids |
| 05/01/2003 | US20030082176 Therapy for metabolism disorders |
| 05/01/2003 | US20030082172 Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| 05/01/2003 | US20030082170 Protein from brucella species |
| 05/01/2003 | US20030082161 Efficient gene therapy; sustained release |
| 05/01/2003 | US20030082154 Fusogenic lipids and vesicles |
| 05/01/2003 | US20030082148 Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo |
| 05/01/2003 | US20030082143 Filamentous phage particles having a ligand on surface for delivering a therapeutic gene to a cell; gene therapy |
| 05/01/2003 | US20030082133 Biocide treating anthrax; highly stable and safe for exposure to human skin; antibiological warfare agents, for surface coatings |
| 05/01/2003 | US20030082128 Homogeneous mixtures of silicone oils and organic oils |
| 05/01/2003 | US20030082118 Use of substituted vinyltetrahydronaphthalenes and vinyl-benzotetrahydropyrans as light protection agents |
| 05/01/2003 | US20030082105 Selectively targeted fluorescent, radiolabeled, or fluorescent and radiolabeled compositions |
| 05/01/2003 | CA2842429A1 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| 05/01/2003 | CA2764642A1 Taste masking spill-resistant formulation |
| 05/01/2003 | CA2675409A1 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| 05/01/2003 | CA2469474A1 Potentiated topical compositions |
| 05/01/2003 | CA2464561A1 Methods of treatment using a gastric retained losartan dosage |
| 05/01/2003 | CA2464349A1 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| 05/01/2003 | CA2464284A1 Magnetic nanodispersion comprising cyclodextrines and method for the production thereof |
| 05/01/2003 | CA2464271A1 Integrin targeting compounds |
| 05/01/2003 | CA2464239A1 Psma antibodies and protein multimers |
| 05/01/2003 | CA2463951A1 Solid pharmaceutical formulation for a piperazine urea derivative |
| 05/01/2003 | CA2463313A1 Stable composition comprising particles in a frozen aqueous matrix |
| 05/01/2003 | CA2463309A1 Sterile, breathable patch for treating wound pain |
| 05/01/2003 | CA2458794A1 Plasticized hydrophilic glasses for improved stabilization of biological agents |
| 04/30/2003 | CN1414965A Sulfonamides and derivatives thereof that modulate the activeity of endothelin |
| 04/30/2003 | CN1414861A Induction of mucosal immunity by vaccination via skin nute |
| 04/30/2003 | CN1414856A Antiprurity agents for external use |
| 04/30/2003 | CN1414855A Remedies for external use for allergic skin diseases |
| 04/30/2003 | CN1414854A Phosphonate compounds |
| 04/30/2003 | CN1414853A Oral mucosal dosage forms of apomorphine |
| 04/30/2003 | CN1414852A Novel composition and use thereof |
| 04/30/2003 | CN1414851A Method and formulation for treating resistance to antihypertensives and related conditions |
| 04/30/2003 | CN1414847A Sustained-releasing antihelmintic compositions comprising praziquantel |
| 04/30/2003 | CN1413743A Vascular suppository material |
| 04/30/2003 | CN1413735A Slow-released carrier with nano structure for drug |
| 04/30/2003 | CN1413577A Thermosensitive long circulation liposome preparation |
| 04/30/2003 | CN1107069C Derivatives of camptothecin for use in treating cancer and its use |
| 04/30/2003 | CN1106858C Vaccine composition having antitumour activity and use there of in therapy of malignant diseases |
| 04/30/2003 | CN1106839C Controlled release of steroids from sugar |
| 04/29/2003 | US6555700 1,3-propane diol esters and ethers and methods for their use in drug delivery |
| 04/29/2003 | US6555692 Polylactams having imidazole or pyrrole rings specifically bind with subnanomolar affinity to a predetermined DNA sequence; use in molecular biology and diagnostic medicine; gene expression control; target the minor groove of B-form |
| 04/29/2003 | US6555675 Dinucleoside polyphosphates which facilitate secretory mechanisms, i.e. increasing the hydration of mucus secretions, stimulating the production of mucins and increasing ciliary beat frequency to facilitate clearance |
| 04/29/2003 | US6555663 Prodrugs for selective drug delivery |
| 04/29/2003 | US6555660 A polypeptide having an amino acid sequence that differs from the preferred granulocyate colony stimulating factor sequence in no more than 15 amino acid residues, and a nonpeptide polymer attached to the amino acid of above polypeptide |
| 04/29/2003 | US6555651 Ligand binding site of rage and uses thereof |
| 04/29/2003 | US6555587 A reagnet binds to a surface by a latent reactive group and presents an aliphatic acid to a physiological environment in manner sufficient to hold and orient albumin |
| 04/29/2003 | US6555582 Eye treatments using synthetic thyroid hormone compositions |
| 04/29/2003 | US6555558 Oral dosage self-emulsifying formulations of pyranone protease inhibitors |
| 04/29/2003 | US6555376 Comprises dissolving surfactants in oil to obtain reverse calcium phosphate micelles of DNA and/or RNA |
| 04/29/2003 | US6555156 Process for making absorbable microparticles |
| 04/29/2003 | US6555146 Sugar-free foodstuff products |
| 04/29/2003 | US6555139 Preparation of micron-size pharmaceutical particles by microfluidization |
| 04/29/2003 | US6555138 Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances |
| 04/29/2003 | US6555136 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 04/29/2003 | US6555133 Oral dosage |
| 04/29/2003 | US6555131 Solid solution of a copolymer of ethyl acrylate and methyl methacrylate containing about 5% trimethylammonium ethyl methacrylate chloride as the sole (meth)acrylate copolymer and an ester of a weak acid as plasticizer |
| 04/29/2003 | US6555129 Transdermal therapeutic system (TTS) containing oxybutynin |
| 04/29/2003 | US6555125 Microbiocides, antiinflammatories, antihistamines and mucoadhesives |
| 04/29/2003 | US6555124 Reversibly increasing the permeability to active agents of epithelial cells; applied orally, sublingually, buccally, rectally, pulmonarily or nasally or through the mucosa of the eye. |
| 04/29/2003 | US6555110 Microencapsulated compounds and method of preparing same |
| 04/29/2003 | US6555108 Implanting HSV-TK retrovirus producing cells to treat tumors |
| 04/29/2003 | US6554853 Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue |
| 04/29/2003 | US6554620 Includes hinokitiol as the active ingredient; enhanced water solubility without the need for alcohol; animal feed additive in granular form; disinfecting the meat of an animal prior to the slaughtering |
| 04/29/2003 | CA2219348C Solvent detergent emulsions having antiviral activity |
| 04/29/2003 | CA2181172C Storage-stable prostaglandin compositions |
| 04/29/2003 | CA2123160C Controlled release formulation |
| 04/26/2003 | WO2003035011A2 Multidrug multiligand conjugates for targeted drug delivery |
| 04/26/2003 | CA2478543A1 Multidrug multiligand conjugates for targeted drug delivery |
| 04/25/2003 | CA2426925A1 Water-soluble liquid internal medicine |
| 04/25/2003 | CA2409910A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| 04/25/2003 | CA2409552A1 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| 04/24/2003 | WO2003034068A1 Localization of disorders associated with kallikreins |
| 04/24/2003 | WO2003033670A2 Method for preparation of single chain antibodies |
| 04/24/2003 | WO2003033653A2 Affinity enhancement agents |
| 04/24/2003 | WO2003033634A1 Low-viscosity opacifiers free from anionic surface-active agents |
| 04/24/2003 | WO2003033593A1 Ph responsive biodegradable polylactic acid derivatives forming polymeric micelles and uses thereof for poorly water soluble drug delivery |
| 04/24/2003 | WO2003033527A2 Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 04/24/2003 | WO2003033525A1 Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament |
| 04/24/2003 | WO2003033445A1 Stabilized compositions of aqueous reduced coenzyme q solution |
| 04/24/2003 | WO2003033028A2 Multimeric proteins |
| 04/24/2003 | WO2003033027A2 Dendrimers for use in targeted delivery |
| 04/24/2003 | WO2003033026A1 Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent |
| 04/24/2003 | WO2003033025A2 Cyclodextrin complexes |
| 04/24/2003 | WO2003033021A1 Use of peptide vectors to improve the immune response to antigens |
| 04/24/2003 | WO2003033015A1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 04/24/2003 | WO2003033012A1 Kahalalide compounds for use in cancer therapy |
| 04/24/2003 | WO2003033010A1 Cyclosporin analogs for the treatment of autoimmune diseases |
| 04/24/2003 | WO2003033000A1 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma |
| 04/24/2003 | WO2003032990A2 Polymer conjugates of opioid antagonists |
| 04/24/2003 | WO2003032983A1 Transdermal migraine therapy |
| 04/24/2003 | WO2003032976A1 Method of treating dermatoses using avermectin compound |